One Capital Management LLC Grows Holdings in Penumbra, Inc. $PEN

One Capital Management LLC grew its holdings in shares of Penumbra, Inc. (NYSE:PEN) by 87.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,629 shares of the company’s stock after buying an additional 5,425 shares during the quarter. One Capital Management LLC’s holdings in Penumbra were worth $3,616,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in PEN. Royal Bank of Canada boosted its stake in shares of Penumbra by 35.8% during the 1st quarter. Royal Bank of Canada now owns 19,332 shares of the company’s stock valued at $5,169,000 after buying an additional 5,092 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Penumbra by 209.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 272 shares of the company’s stock valued at $70,000 after buying an additional 184 shares during the last quarter. Cerity Partners LLC boosted its stake in shares of Penumbra by 22.3% during the 2nd quarter. Cerity Partners LLC now owns 10,030 shares of the company’s stock valued at $2,574,000 after buying an additional 1,829 shares during the last quarter. California Public Employees Retirement System boosted its stake in shares of Penumbra by 7.9% during the 2nd quarter. California Public Employees Retirement System now owns 61,027 shares of the company’s stock valued at $15,661,000 after buying an additional 4,491 shares during the last quarter. Finally, Daiwa Securities Group Inc. purchased a new position in shares of Penumbra during the 2nd quarter valued at approximately $1,137,000. 88.88% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Penumbra

In related news, Director Harpreet Grewal sold 100 shares of Penumbra stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $328.22, for a total transaction of $32,822.00. Following the sale, the director directly owned 8,719 shares in the company, valued at $2,861,750.18. The trade was a 1.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.90% of the stock is currently owned by corporate insiders.

Penumbra Stock Down 0.1%

PEN stock opened at $318.66 on Wednesday. Penumbra, Inc. has a fifty-two week low of $221.26 and a fifty-two week high of $362.41. The firm’s 50-day simple moving average is $328.12 and its 200 day simple moving average is $325.22. The company has a quick ratio of 3.95, a current ratio of 6.02 and a debt-to-equity ratio of 0.01. The stock has a market cap of $12.53 billion, a PE ratio of 73.42, a price-to-earnings-growth ratio of 1.95 and a beta of 0.71.

Penumbra (NYSE:PEN) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.82 earnings per share for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.24). Penumbra had a net margin of 11.76% and a return on equity of 10.87%. The company had revenue of $374.76 million for the quarter, compared to the consensus estimate of $370.47 million. During the same quarter in the prior year, the firm earned $0.83 earnings per share. Penumbra’s revenue for the quarter was up 15.6% compared to the same quarter last year. As a group, sell-side analysts predict that Penumbra, Inc. will post 5.08 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Wall Street Zen upgraded Penumbra to a “hold” rating in a research note on Saturday, May 9th. Citigroup reduced their price objective on Penumbra from $374.00 to $350.00 and set a “neutral” rating on the stock in a research note on Thursday, May 7th. Evercore restated an “outperform” rating and set a $335.00 price objective on shares of Penumbra in a research note on Thursday, May 7th. Finally, UBS Group restated a “neutral” rating and set a $374.00 price objective on shares of Penumbra in a research note on Thursday, February 26th. Three investment analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $361.33.

Penumbra Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.